Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
about
Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report.Prolonged duration of response in lenvatinib responders with thyroid cancer.Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
P2860
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence and timing of common ...... iation with survival outcomes.
@en
Incidence and timing of common ...... iation with survival outcomes.
@nl
type
label
Incidence and timing of common ...... iation with survival outcomes.
@en
Incidence and timing of common ...... iation with survival outcomes.
@nl
prefLabel
Incidence and timing of common ...... iation with survival outcomes.
@en
Incidence and timing of common ...... iation with survival outcomes.
@nl
P2093
P2860
P1433
P1476
Incidence and timing of common ...... iation with survival outcomes.
@en
P2093
Andrew G Gianoukakis
Angela Teng
Bruce Robinson
Corina E Dutcus
Eric J Sherman
Lori J Wirth
Manisha H Shah
Martin Schlumberger
Robert I Haddad
Steven I Sherman
P2860
P2888
P304
P356
10.1007/S12020-017-1233-5
P577
2017-02-03T00:00:00Z